… for drug development that leverage cooperativity by reducing … pneumonia (COVID-19),
triggered by SARS-CoV-2, has had … that targeting PLpro with drugs not only inhibits SARS-CoV-2 …

… limited use against COVID-19 4,5 . However, the emergence of … a cornerstone when
designing novel antiviral drugs 6 . … MD simulations of the SARS-CoV-2 PL pro . Each analyzed …

… in most countries following the COVID-19 pandemic, our generic … We underscore those
SARS-CoV-2 M pro , PL pro , and … early stages of antiviral drug design by extracting evolutionary …

… development of antivirals for the treatment of COVID-19, in … with activity against RNA viruses
that may be leveraged as a … methods to SARS-CoV-2 3CLpro and PLpro with a collaborative …

… a binding mode for this inhibitor to PL pro distinct from other … -based inhibitors designed
based on the peptide substrate of … inhibits PLpro will be very useful as a treatment for COVID-19. …

… inhibitors and treatment options for the MPro of SARS-CoV-2 … understand the implications of
PLpro mutations on viral pathogenicity … By fostering international cooperation and leveraging …

… a lot due to massive COVID-19 vaccination programs. Drug … for any ligand to leverage binding
to multiple sites on PLpro. Four … The compounds designed by this research group failed to …

… A could be leveraged for SARS-CoV-2 antiviral activity. … potential of CatL as a COVID-19
antiviral target and the likely … at 10 μM for inhibition against SARS-CoV-2 Mpro and PLpro. …

… potential of cathepsin L as a COVID-19 antiviral drug target. … A could be leveraged for
SARS-CoV-2 antiviral activity. … at 10 μM for inhibition against SARS-CoV-2 Mpro and PLpro. …

… ) of SARS-CoV-2 could be quickly repurposed for COVID-19. For … to find efficacious inhibitors
for SARS-CoV-2’s PLpro, we … In summary, leveraging our powerful HPC cluster, we applied …